Mukka Proteins to issue 2 crore warrants convertible to equity shares worth ₹47 crore on preferential basis
Mukka Proteins will issue up to 2 crore warrants convertible into equity shares on a preferential basis. The total issue size is ₹47 crore, with each warrant priced at ₹23.50. Conversion into shares is permitted within 18 months. E-voting for shareholder approval runs from June 13, 2026, to July 12, 2026.
The preferential issue of warrants will increase the equity base and raise capital, which can impact the company's financial structure and potentially its share price. The amount raised is significant relative to the company's size.
The company is raising capital through the issuance of warrants, which is generally a positive sign for growth and expansion.
Mukka Proteins Limited has announced a postal ballot notice dated 12th June 2026, seeking shareholder approval for a preferential issue of up to 2,00,00,000 (Two Crore) warrants convertible into equity shares. The issue price for each warrant is fixed at ₹23.50, aggregating to a total issue size of ₹47,00,00,000 (Rupees Forty-Seven Crores Only).
The warrants will be convertible into fully paid-up equity shares of face value ₹1 each, at a premium of ₹22.50 per share, within a period of 18 months from the date of allotment. The relevant date for determining the floor price for the issue is June 12, 2026.
The e-voting period for the postal ballot commences on Saturday, June 13, 2026, at 9:00 a.m. and concludes on Sunday, July 12, 2026, at 5:00 p.m. The results of the voting will be announced within two working days from the conclusion of the remote e-voting. The company will not dispatch physical copies of the notice or accept physical ballot forms; all voting will be conducted through remote e-voting.
Key proposed allottees for these warrants, belonging to the non-promoter category, include Mr. Irfan Chapra, Ms. Reshma Chapra, Mr. Vishal Maniar, Ms. Payal Maniar, and others. The company has appointed Mr. Chethan Nayak K and Mrs. Ujala Rani as scrutinizers for the postal ballot process.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.